INTRODUCTION Docetaxel use was first found to prolong overall survival (OS) in patients with metastatic castration-resistant prostate cancer.1, 2 Subsequently, docetaxel use was studied in the metastatic castration-sensitive prostate cancer (mCSPC) setting, and found to prolong OS in patients with high-volume metastatic disease when added to the standard of care (SOC) at the time of androgen deprivation therapy (ADT).3, 4 Later, on the basis of the results of two randomized trials, six cycles...
Ming-Hui Chen
As seen in:
Wiley Online Library,
PLOS ONE,
Frontiers,
JAMA Oncology,
BioRxiv,
Dove Medical Press,
European Urology
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ming-Hui
Contact Ming-Hui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack